{"pmid":32369628,"title":"Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease - has not received enough attention till date.","text":["Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease - has not received enough attention till date.","One of the hallmarks of COVID-19 is a reduction in lymphocyte counts, and the degree of reduction correlates with disease severity. Studies have shown a linear negative correlation between peripheral blood CD8+ T cells counts and viral copy numbers in nasopharynx and disease severity. In addition, CD8+ T cells are reported to be functionally 'exhausted'. Currently, there is no proven treatment for COVID-19. Cytotoxic T cells are key to fighting intracellular viruses. In the context of haematopoietic stem cell transplantation, a variety of viral infections have been successfully treated using off-the-shelf HLA-matched virus-specific cytotoxic T cells. A similar strategy using convalescent donor CD8+ T cells appears to be the need of the hour and has not received enough attention till date.","Br J Haematol","Hanley, Brian","Roufosse, Candice A","Osborn, Michael","Naresh, Kikkeri N","32369628"],"abstract":["One of the hallmarks of COVID-19 is a reduction in lymphocyte counts, and the degree of reduction correlates with disease severity. Studies have shown a linear negative correlation between peripheral blood CD8+ T cells counts and viral copy numbers in nasopharynx and disease severity. In addition, CD8+ T cells are reported to be functionally 'exhausted'. Currently, there is no proven treatment for COVID-19. Cytotoxic T cells are key to fighting intracellular viruses. In the context of haematopoietic stem cell transplantation, a variety of viral infections have been successfully treated using off-the-shelf HLA-matched virus-specific cytotoxic T cells. A similar strategy using convalescent donor CD8+ T cells appears to be the need of the hour and has not received enough attention till date."],"journal":"Br J Haematol","authors":["Hanley, Brian","Roufosse, Candice A","Osborn, Michael","Naresh, Kikkeri N"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369628","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16780","topics":["Treatment"],"weight":1,"_version_":1666138496247529473,"score":9.490897,"similar":[{"pmid":32344314,"pmcid":"PMC7194824","title":"Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents.","text":["Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents.","Following the outbreak of a novel coronavirus (SARS-CoV-2), studies suggest that the resultant disease (COVID-19) is more severe in individuals with a weakened immune system. Cytotoxic T-cells (CTLs) and Natural Killer (NK) cells are required to generate an effective immune response against viruses, functional exhaustion of which enables disease progression. Patients with severe COVID-19 present significantly lower lymphocyte, and higher neutrophil, counts in blood. Specifically, CD8(+) lymphocytes and NK cells were significantly reduced in cases of severe infection compared to patients with mild infection and healthy individuals. The NK group 2 member A (NKG2A) receptor transduces inhibitory signalling, suppressing NK cytokine secretion and cytotoxicity. Overexpression of NKG2A has been observed on CD8(+) and NK cells of COVID-19 infected patients compared to healthy controls, while NKG2A overexpression also functionally exhausts CD8(+) cells and NK cells, resulting in a severely compromised innate immune response. Blocking NKG2A on CD8(+) cells and NK cells in cancers modulated tumor growth, restoring CD8(+) T and NK cell function. A recently proposed mechanism via which SARS-CoV-2 overrides innate immune response of the host is by over-expressing NKG2A on CD(+) T and NK cells, culminating in functional exhaustion of the immune response against the viral pathogen. Monalizumab is an inhibiting antibody against NKG2A which can restore the function of CD8 + T and NK cells in cancers, successfully ceasing tumor progression with no significant side effects in Phase 2 clinical trials. We hypothesize that patients with severe COVID-19 have a severely compromised innate immune response and could be treated via the use of Monalizumab, interferon alpha, chloroquine, and other antiviral agents.","Med Hypotheses","Yaqinuddin, Ahmed","Kashir, Junaid","32344314"],"abstract":["Following the outbreak of a novel coronavirus (SARS-CoV-2), studies suggest that the resultant disease (COVID-19) is more severe in individuals with a weakened immune system. Cytotoxic T-cells (CTLs) and Natural Killer (NK) cells are required to generate an effective immune response against viruses, functional exhaustion of which enables disease progression. Patients with severe COVID-19 present significantly lower lymphocyte, and higher neutrophil, counts in blood. Specifically, CD8(+) lymphocytes and NK cells were significantly reduced in cases of severe infection compared to patients with mild infection and healthy individuals. The NK group 2 member A (NKG2A) receptor transduces inhibitory signalling, suppressing NK cytokine secretion and cytotoxicity. Overexpression of NKG2A has been observed on CD8(+) and NK cells of COVID-19 infected patients compared to healthy controls, while NKG2A overexpression also functionally exhausts CD8(+) cells and NK cells, resulting in a severely compromised innate immune response. Blocking NKG2A on CD8(+) cells and NK cells in cancers modulated tumor growth, restoring CD8(+) T and NK cell function. A recently proposed mechanism via which SARS-CoV-2 overrides innate immune response of the host is by over-expressing NKG2A on CD(+) T and NK cells, culminating in functional exhaustion of the immune response against the viral pathogen. Monalizumab is an inhibiting antibody against NKG2A which can restore the function of CD8 + T and NK cells in cancers, successfully ceasing tumor progression with no significant side effects in Phase 2 clinical trials. We hypothesize that patients with severe COVID-19 have a severely compromised innate immune response and could be treated via the use of Monalizumab, interferon alpha, chloroquine, and other antiviral agents."],"journal":"Med Hypotheses","authors":["Yaqinuddin, Ahmed","Kashir, Junaid"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344314","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.mehy.2020.109777","keywords":["covid-19","innate immunity","monalizumab","nkg2a","sars"],"locations":["Monalizumab"],"e_drugs":["Chloroquine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495873187840,"score":260.06622},{"pmid":32492530,"title":"Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity.","text":["Aberrant hyperactivation of cytotoxic T-cell as a potential determinant of COVID-19 severity.","OBJECTIVES: We hypothesized that immune response may contribute to progression of coronavirus disease-19 (COVID-19) at the second week of illness. Therefore, we compared cell-mediated immune (CMI) responses between severe and mild COVID-19 cases. METHODS: We examined peripheral blood mononuclear cells of laboratory-confirmed COVID-19 patients from their first and third weeks of illness. Severe pneumonia was defined as an oxygen saturation </= 93% at room air. Expressions of molecules related to T-cell activation and functions were analyzed by flow cytometry. RESULTS: The population dynamics of T cells at the first week were not different between the two groups. However, total numbers of CD4+ and CD8 + T cells tended to be lower in the severe group at the third week of illness. Expressions of Ki-67, PD-1, perforin, and granzyme B in CD4(+) or CD8(+) T cells were significantly higher in the severe group than in the mild group at the third week. In contrast to the mild group, the levels of their expression did not decrease in severe group. CONCLUSIONS: Severe COVID-19 had higher degree of proliferation, activation, and cytotoxicity of T-cells at the late phase of illness without cytotoxic T-cell contraction, which might contribute to the development of severe COVID-19.","Int J Infect Dis","Kang, Chang Kyung","Han, Gi-Chan","Kim, Minji","Kim, Gwanghun","Shin, Hyun Mu","Song, Kyoung-Ho","Choe, Pyoeng Gyun","Park, Wan Beom","Kim, Eu Suk","Kim, Hong Bin","Kim, Nam-Joong","Kim, Hang-Rae","Oh, Myoung-Don","32492530"],"abstract":["OBJECTIVES: We hypothesized that immune response may contribute to progression of coronavirus disease-19 (COVID-19) at the second week of illness. Therefore, we compared cell-mediated immune (CMI) responses between severe and mild COVID-19 cases. METHODS: We examined peripheral blood mononuclear cells of laboratory-confirmed COVID-19 patients from their first and third weeks of illness. Severe pneumonia was defined as an oxygen saturation </= 93% at room air. Expressions of molecules related to T-cell activation and functions were analyzed by flow cytometry. RESULTS: The population dynamics of T cells at the first week were not different between the two groups. However, total numbers of CD4+ and CD8 + T cells tended to be lower in the severe group at the third week of illness. Expressions of Ki-67, PD-1, perforin, and granzyme B in CD4(+) or CD8(+) T cells were significantly higher in the severe group than in the mild group at the third week. In contrast to the mild group, the levels of their expression did not decrease in severe group. CONCLUSIONS: Severe COVID-19 had higher degree of proliferation, activation, and cytotoxicity of T-cells at the late phase of illness without cytotoxic T-cell contraction, which might contribute to the development of severe COVID-19."],"journal":"Int J Infect Dis","authors":["Kang, Chang Kyung","Han, Gi-Chan","Kim, Minji","Kim, Gwanghun","Shin, Hyun Mu","Song, Kyoung-Ho","Choe, Pyoeng Gyun","Park, Wan Beom","Kim, Eu Suk","Kim, Hong Bin","Kim, Nam-Joong","Kim, Hang-Rae","Oh, Myoung-Don"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492530","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ijid.2020.05.106","keywords":["covid-19","contraction","cytotoxic t cell","granzyme b","perforin","severity"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668623433541353472,"score":234.85518},{"pmid":32325421,"pmcid":"PMC7194879","title":"Increased expression of CD8 marker on T-cells in COVID-19 patients.","text":["Increased expression of CD8 marker on T-cells in COVID-19 patients.","BACKGROUND: Cell-mediated immunity including T-cells (T helper and cytotoxic) plays an essential role in efficient antiviral responses against coronavirus disease-2019 (COVID-19). Therefore, in this study, we evaluated the ratio and expression of CD4 and CD8 markers in COVID-19 patients to clarify the immune characterizations of CD4 and CD8 T-cells in COVID-19 patients. METHODS: Peripheral blood samples of 25 COVID-19 patients and 25 normal individuals with similar age and sex as the control group were collected. White blood cells, platelets, and lymphocytes were counted and CD4 and CD8 T lymphocytes were evaluated by flow cytometry. RESULTS: The number of white blood cells, lymphocytes, and platelets were reduced significantly in COVID-19 patients (P < 0.05). The difference in CD4:CD8 ratio, CD4 T-cell frequency, CD8 T-cell frequency, and CD4 mean fluorescence intensity (MFI) was not significant between COVID-19 patients and healthy individuals (P > 0.05); however, the CD8 MFI increased significantly in COVID-19 infected patients (P < 0.05). CONCLUSION: Although, there is no significant difference in the ratio of CD4 to CD8 between two groups, the expression level of CD8 in COVID-19 patients was significantly higher than the normal individuals. This result suggested that the cellular immune responses triggered by COVID-19 infection were developed through overexpression of CD8 and hyperactivation of cytotoxic T lymphocytes.","Blood Cells Mol Dis","Ganji, Ali","Farahani, Iman","Khansarinejad, Behzad","Ghazavi, Ali","Mosayebi, Ghasem","32325421"],"abstract":["BACKGROUND: Cell-mediated immunity including T-cells (T helper and cytotoxic) plays an essential role in efficient antiviral responses against coronavirus disease-2019 (COVID-19). Therefore, in this study, we evaluated the ratio and expression of CD4 and CD8 markers in COVID-19 patients to clarify the immune characterizations of CD4 and CD8 T-cells in COVID-19 patients. METHODS: Peripheral blood samples of 25 COVID-19 patients and 25 normal individuals with similar age and sex as the control group were collected. White blood cells, platelets, and lymphocytes were counted and CD4 and CD8 T lymphocytes were evaluated by flow cytometry. RESULTS: The number of white blood cells, lymphocytes, and platelets were reduced significantly in COVID-19 patients (P < 0.05). The difference in CD4:CD8 ratio, CD4 T-cell frequency, CD8 T-cell frequency, and CD4 mean fluorescence intensity (MFI) was not significant between COVID-19 patients and healthy individuals (P > 0.05); however, the CD8 MFI increased significantly in COVID-19 infected patients (P < 0.05). CONCLUSION: Although, there is no significant difference in the ratio of CD4 to CD8 between two groups, the expression level of CD8 in COVID-19 patients was significantly higher than the normal individuals. This result suggested that the cellular immune responses triggered by COVID-19 infection were developed through overexpression of CD8 and hyperactivation of cytotoxic T lymphocytes."],"journal":"Blood Cells Mol Dis","authors":["Ganji, Ali","Farahani, Iman","Khansarinejad, Behzad","Ghazavi, Ali","Mosayebi, Ghasem"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32325421","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.bcmd.2020.102437","keywords":["2019-ncov","cd4 lymphocyte","cd8 lymphocyte","covid-19","coronavirus"],"topics":["Mechanism"],"weight":1,"_version_":1666138493884039168,"score":229.52275},{"pmid":32463803,"title":"Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.","text":["Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.","BACKGROUND: Coronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Anti-viral immune response is crucial to achieve pathogen clearance, however in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options. METHODS: We performed a flow cytometric characterization of immune cells subsets from 30 COVID-19 patients and correlated these data with clinical outcomes. RESULTS: COVID-19 patients showed decreased numbers of circulating T, B and NK cells, and exhibited a skewing of CD8+ T cells towards a terminally differentiated/senescent phenotype. In agreement, T CD4+, T CD8+ but also NK cells displayed reduced anti-viral cytokine production capability. Moreover, a reduced cytotoxic potential was identified in COVID-19 patients, particularly in those that required intensive care. The latter group of patients showed also increased serum IL-6 levels, that correlated to the frequency of granzyme-expressing NK cells. Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells. CONCLUSION: In conclusion, the association between IL-6 serum levels and the impairment of cytotoxic activity suggests the possibility that targeting this cytokine may restore anti-viral mechanisms. FUNDING: This study was supported by funds of Dept. of Experimental and Clinical Medicine of University of Florence (ex-60%) derived from Ministero dell'Istruzione, dell'Universita e della Ricerca (Italy).","J Clin Invest","Mazzoni, Alessio","Salvati, Lorenzo","Maggi, Laura","Capone, Manuela","Vanni, Anna","Spinicci, Michele","Mencarini, Jessica","Caporale, Roberto","Peruzzi, Benedetta","Antonelli, Alberto","Trotta, Michele","Zammarchi, Lorenzo","Ciani, Luca","Gori, Leonardo","Lazzeri, Chiara","Matucci, Andrea","Vultaggio, Alessandra","Rossi, Oliviero","Almerigogna, Fabio","Parronchi, Paola","Fontanari, Paolo","Lavorini, Federico","Peris, Adriano","Rossolini, Gian Maria","Bartoloni, Alessandro","Romagnani, Sergio","Liotta, Francesco","Annunziato, Francesco","Cosmi, Lorenzo","32463803"],"abstract":["BACKGROUND: Coronavirus disease 19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2. Anti-viral immune response is crucial to achieve pathogen clearance, however in some patients an excessive and aberrant host immune response can lead to an acute respiratory distress syndrome. The comprehension of the mechanisms that regulate pathogen elimination, immunity, and pathology is essential to better characterize disease progression and widen the spectrum of therapeutic options. METHODS: We performed a flow cytometric characterization of immune cells subsets from 30 COVID-19 patients and correlated these data with clinical outcomes. RESULTS: COVID-19 patients showed decreased numbers of circulating T, B and NK cells, and exhibited a skewing of CD8+ T cells towards a terminally differentiated/senescent phenotype. In agreement, T CD4+, T CD8+ but also NK cells displayed reduced anti-viral cytokine production capability. Moreover, a reduced cytotoxic potential was identified in COVID-19 patients, particularly in those that required intensive care. The latter group of patients showed also increased serum IL-6 levels, that correlated to the frequency of granzyme-expressing NK cells. Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells. CONCLUSION: In conclusion, the association between IL-6 serum levels and the impairment of cytotoxic activity suggests the possibility that targeting this cytokine may restore anti-viral mechanisms. FUNDING: This study was supported by funds of Dept. of Experimental and Clinical Medicine of University of Florence (ex-60%) derived from Ministero dell'Istruzione, dell'Universita e della Ricerca (Italy)."],"journal":"J Clin Invest","authors":["Mazzoni, Alessio","Salvati, Lorenzo","Maggi, Laura","Capone, Manuela","Vanni, Anna","Spinicci, Michele","Mencarini, Jessica","Caporale, Roberto","Peruzzi, Benedetta","Antonelli, Alberto","Trotta, Michele","Zammarchi, Lorenzo","Ciani, Luca","Gori, Leonardo","Lazzeri, Chiara","Matucci, Andrea","Vultaggio, Alessandra","Rossi, Oliviero","Almerigogna, Fabio","Parronchi, Paola","Fontanari, Paolo","Lavorini, Federico","Peris, Adriano","Rossolini, Gian Maria","Bartoloni, Alessandro","Romagnani, Sergio","Liotta, Francesco","Annunziato, Francesco","Cosmi, Lorenzo"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463803","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1172/JCI138554","keywords":["cellular immune response","cytokines","immunology","infectious disease","nk cells"],"locations":["Dept. of"],"countries":["Turkey"],"countries_codes":["TUR|Turkey"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521480310785,"score":224.63084},{"pmid":32442287,"title":"Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.","text":["Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.","BACKGROUND: We previously reported that lymphocytopenia and T cell exhaustion is notable in acute COVID19 patients, especially in aged and severe cases. Thymosin alpha 1 (Talpha1) had been used in the treatment of viral infections as an immune response modifier for many years. However, clinical benefits and mechanism of Talpha1 supplement to COVID-19 are still unclear. METHODS: We retrospectively reviewed the clinical outcomes of 76 severe cases with COVID-19 admitted into two hospitals in Wuhan from December 2019 to March 2020. The thymus output in peripheral blood mononuclear cells (PBMCs) from COVID-19 patients was measured by T cell receptor excision circles (TREC). The levels of T cell exhaustion markers PD-1 and Tim-3 on CD8+ T cells were detected by flow cytometry. RESULTS: Compared with untreated group, Talpha1 treatment significantly reduces mortality of severe COVID-19 patients (11.11% vs. 30.00%, p=0.044). Talpha1 timely enhances blood T cell numbers in COVID-19 patients with severe lymphocytopenia (the counts of CD8+ T cells or CD4+ T cells in circulation lower than 400/muL or 650/muL, respectively). Under such conditions, Talpha1 also successfully restores CD8+ and CD4+ T cell numbers in aged patients. Meanwhile, Talpha1 reduces PD-1 and Tim-3 expression on CD8+ T cells from severe COVID-19 patients in comparison with untreated cases. It is of note that restoration of lymphocytopenia and acute exhaustion of T cells are roughly parallel to the rise of TRECs. CONCLUSIONS: Talpha1 supplement significantly reduce mortality of severe COVID-19 patients. COVID-19 patients with the counts of CD8+ T cells or CD4+ T cells in circulation lower than 400/muL or 650/muL, respectively, gain more benefits from Talpha1. Talpha1 reverses T cell exhaustion and recovers immune reconstitution through promoting thymus output during SARS-CoV-2 infection.","Clin Infect Dis","Liu, Yueping","Pang, Yue","Hu, Zhenhong","Wu, Ming","Wang, Chenhui","Feng, Zeqing","Mao, Congzheng","Tan, Yingjun","Liu, Ying","Chen, Li","Li, Min","Wang, Gang","Yuan, Zilin","Diao, Bo","Wu, Yuzhang","Chen, Yongwen","32442287"],"abstract":["BACKGROUND: We previously reported that lymphocytopenia and T cell exhaustion is notable in acute COVID19 patients, especially in aged and severe cases. Thymosin alpha 1 (Talpha1) had been used in the treatment of viral infections as an immune response modifier for many years. However, clinical benefits and mechanism of Talpha1 supplement to COVID-19 are still unclear. METHODS: We retrospectively reviewed the clinical outcomes of 76 severe cases with COVID-19 admitted into two hospitals in Wuhan from December 2019 to March 2020. The thymus output in peripheral blood mononuclear cells (PBMCs) from COVID-19 patients was measured by T cell receptor excision circles (TREC). The levels of T cell exhaustion markers PD-1 and Tim-3 on CD8+ T cells were detected by flow cytometry. RESULTS: Compared with untreated group, Talpha1 treatment significantly reduces mortality of severe COVID-19 patients (11.11% vs. 30.00%, p=0.044). Talpha1 timely enhances blood T cell numbers in COVID-19 patients with severe lymphocytopenia (the counts of CD8+ T cells or CD4+ T cells in circulation lower than 400/muL or 650/muL, respectively). Under such conditions, Talpha1 also successfully restores CD8+ and CD4+ T cell numbers in aged patients. Meanwhile, Talpha1 reduces PD-1 and Tim-3 expression on CD8+ T cells from severe COVID-19 patients in comparison with untreated cases. It is of note that restoration of lymphocytopenia and acute exhaustion of T cells are roughly parallel to the rise of TRECs. CONCLUSIONS: Talpha1 supplement significantly reduce mortality of severe COVID-19 patients. COVID-19 patients with the counts of CD8+ T cells or CD4+ T cells in circulation lower than 400/muL or 650/muL, respectively, gain more benefits from Talpha1. Talpha1 reverses T cell exhaustion and recovers immune reconstitution through promoting thymus output during SARS-CoV-2 infection."],"journal":"Clin Infect Dis","authors":["Liu, Yueping","Pang, Yue","Hu, Zhenhong","Wu, Ming","Wang, Chenhui","Feng, Zeqing","Mao, Congzheng","Tan, Yingjun","Liu, Ying","Chen, Li","Li, Min","Wang, Gang","Yuan, Zilin","Diao, Bo","Wu, Yuzhang","Chen, Yongwen"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442287","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1093/cid/ciaa630","keywords":["covid-19","immune reconstitution","sars-cov-2","t cell exhaustion","thymosin alpha 1"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667523504761733120,"score":204.70677}]}